一项多中心、随机、双盲、安慰剂对照的2a期研究,包含开放标签扩展期,旨在评估VENT-03在患有活动性皮肤红斑狼疮(伴或不伴系统性红斑狼疮)成年参与者中的疗效和安全性 (AERIS)
一项多中心、随机、双盲、安慰剂对照的2a期研究,含开放标签扩展期,旨在评估VENT-03在伴有或不伴有系统性红斑狼疮的活动性皮肤红斑狼疮成年参与者中的疗效和安全性
The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE). Another goal is to learn about the safety of VENT-03 and how it is processed by the body. The main questions it aims to answer are:
- Does VENT-03 affect the activity and severity of CLE?
- What side effects do participants have when taking VENT-03?
Researchers will compare VENT-03 to a placebo (a look-alike substance that contains no drug) to see if VENT-03 works to treat patients with CLE.
Participants will:
- Take VENT-03 or a placebo for 4 weeks, then all participants will switch to VENT-03 for another 8 weeks;
- Visit the clinic once a month for checkups and tests.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Tbilisi、乔治亚州
- Investigative Site
-
-
-
-
-
Haskovo、保加利亚
- Investigative Site
-
Plovdiv、保加利亚
- Investigative Site
-
Sofia、保加利亚
- Investigative Site
-
-
-
-
-
Szeged、匈牙利
- Investigative Site
-
-
-
-
-
Durban、南非
- Investigative Site
-
Pretoria、南非
- Investigative Site
-
Somerset West、南非
- Investigative Site
-
-
-
-
-
Paris、法国
- Investigative Site
-
Toulouse、法国
- Investigative Site
-
-
-
-
-
Bialystok、波兰
- Investigative Site
-
Oświęcim、波兰
- Investigative Site
-
Poznan、波兰
- Investigative Site
-
Rzeszów、波兰
- Investigative Site
-
Warsaw、波兰
- Investigative Site
-
Wroclaw、波兰
- Investigative Site
-
Śląskie、波兰
- Investigative Site
-
-
-
-
California
-
Beverly Hills、California、美国、90211
- Investigative Site
-
-
Florida
-
Clearwater、Florida、美国、33765
- Investigative Site
-
DeBary、Florida、美国、32713
- Investigative Site
-
Miami、Florida、美国、33133
- Investigative Site
-
Tampa、Florida、美国、33606
- Investigative Site
-
-
Indiana
-
Indianapolis、Indiana、美国、46250
- Investigative Site
-
-
Michigan
-
Flint、Michigan、美国、48439
- Investigative Site
-
Troy、Michigan、美国、48084
- Investigative Site
-
-
Missouri
-
Saint Joseph、Missouri、美国、64506
- Investigative Site
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87102
- Investigative Site
-
-
New York
-
Fairport、New York、美国、14450
- Investigative Site
-
-
Tennessee
-
Memphis、Tennessee、美国、38119
- Investigative Site
-
-
Texas
-
Allen、Texas、美国、75013
- Investigative Site
-
Arlington、Texas、美国、76012
- Investigative Site
-
Colleyville、Texas、美国、76034
- Investigative Site
-
-
-
-
-
Badajoz、西班牙
- Investigative Site
-
Madrid、西班牙
- Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
-
Cutaneous lupus:
- CLASI-A score ≥8;
- At least 1 active discoid lupus erythematosus (DLE) lesion, OR at least 1 active subacute CLE lesion
-
If participant has previous SLE diagnosis:
- Positive antinuclear antibody test at Screening by immunofluorescent assay at the central laboratory with titer ≥ 1:80;
- Meets the American College of Rheumatology/ European Alliance of Associations for Rheumatology 2019 criteria for SLE; and
- Currently receiving at least one of the specified SLE medication treatments, at stable doses.
Key Exclusion Criteria:
- Meet protocol-specified infection or lab criteria; any other laboratory test results that, in the investigator's opinion, might place participant at unacceptable risk for participating in this study;
- Moderate or severe liver impairment as classified by the Child-Pugh criteria (categories B and C);
- Has drug-induced lupus, rather than 'idiopathic' lupus;
- History of, or current, inflammatory joint or skin disease other than SLE and cutaneous lupus;
- Diagnosis of select potentially confounding autoimmune disorders
- Active severe or unstable neuropsychiatric SLE;
- Hospitalization for a severe lupus flare in the past 3 months, or active severe SLE-driven disease, including lupus nephritis, for which in the opinion of the PI the protocol-specified SOC is insufficient;
- History of or current diagnosis of anti-phospholipid syndrome;
- History of any non-lupus disease that has required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to Day 1;
- Meets protocol specified medical history of infectious diseases and infections and/or opportunistic infection requiring hospitalization or parenteral antimicrobial treatment within specified timeframes;
- Cancer screening results suspicious of malignancy or history of cancer within time specified with exceptions for curative therapy for squamous or basil cell carcinoma and cervical cancer in situ; and
- Meets protocol specified exclusions related to concomitant medications.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Placebo
Placebo |
Placebo is a tablet |
|
实验性的:VENT-03
VENT-03 |
VENT-03 is a tablet |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Evaluate the effect of VENT-03 on the interferon gene signature in the skin
大体时间:Baseline to End of Double-Blind Treatment (up to Day 28)
|
Percent change from baseline in interferon gene signature in the skin at Day 28 |
Baseline to End of Double-Blind Treatment (up to Day 28)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
皮肤活检中粘液病毒抗性蛋白A(MXA)免疫染色的基线变化
大体时间:基线至治疗结束(最多84天)
|
基线至治疗结束(最多84天)
|
|
|
Cmax:VENT-03 的最大观测血浆浓度
大体时间:第1天给药前和给药后多个时间点(最长6小时);第28天给药前和给药后;第56天和第84天给药前
|
第1天给药前和给药后多个时间点(最长6小时);第28天给药前和给药后;第56天和第84天给药前
|
|
|
AUClast:VENT-03 从时间 0 到最后可定量浓度时间的血浆浓度-时间曲线下面积
大体时间:第1天给药前和给药后多个时间点(最长6小时);第28天给药前和给药后;第56天和第84天给药前
|
第1天给药前和给药后多个时间点(最长6小时);第28天给药前和给药后;第56天和第84天给药前
|
|
|
发生中度或重度治疗期间不良事件(TEAEs)的参与者数量
大体时间:基线至治疗结束(最多84天)
|
基线至治疗结束(最多84天)
|
|
|
发生≥1次导致治疗中断的治疗中出现的不良事件(AE)的参与者百分比
大体时间:基线至治疗结束(至第84天)
|
基线至治疗结束(至第84天)
|
|
|
Evaluate the effect of VENT-03 on CLE disease severity
大体时间:Baseline to End of Double-Blind Treatment (up to Day 28)
|
Percent change from baseline in CLASI-A score at Day 28 |
Baseline to End of Double-Blind Treatment (up to Day 28)
|
|
Evaluate effect of VENT-03 on CLE disease severity
大体时间:Baseline to End of Double-Blind Treatment (up to Day 28)
|
Percentage of participants achieving CLASI-A 50 response (≥ 50% improvement in CLASI A score compared with baseline) at Day 28 |
Baseline to End of Double-Blind Treatment (up to Day 28)
|
|
Number of participants with at least one Treatment Emergent Adverse Event (TEAE) and/or Serious Adverse Event (SAE)
大体时间:Baseline to End of Treatment (up to Day 84)
|
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an AE with an onset that occurs after receiving study drug. An SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. |
Baseline to End of Treatment (up to Day 84)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- VENT-03-201
- 2024-520098-12-00 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
As this study will enroll patients from the EU, the sponsor needs to consider that an IPD plan is compliant with GDPR. The sponsor needs to analyze and determine whether an IPD Plan can comply with GDPR based on plans and processes in place for the study in order to ensure legality and ethical data handling.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.